Personalized Medicine and the Affordable Care Act

Grant D. Lawless, RPh, MD, FACP

Video Categories: Affordable Care Act

Grant Lawless discusses the long term goal of personalized medicine as it relates to the Affordable Care Act
March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

July 13, 2021

Real-World Management of Thyroid Cancer with TRK Inhibitors

Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Mary Fidler of Rush University Medical Center, Chicago, IL, recount their clinical experiences and the journeys of patients treated with TRK inhibitors for thyroid cancer.